| Today’s Big NewsMar 20, 2024 |
| By Ben Adams It’s March, so it’s time for some #FierceMadness. Last year, we channeled the NCAA tournament for the best pharma ad campaigns, but this year we’re looking for the best of the best in drug names. |
|
|
|
By Fraiser Kansteiner After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy in the U.S., Kyowa Kirin and its subsidiary Orchard Therapeutics have broken new boundaries in pricing, too. |
By Conor Hale A little more than a year after announcing plans to move its molecule design programs into the field of generative AI, Nvidia is setting up shop. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
|
Wednesday, March 27, 2024 | 10am ET / 7am PTThere can be numerous challenges encountered during biopharmaceutical process development. Join usfor an important look at formulation development specifically. Featuring real-world examples, this insightful discussion will explore key challenges, as well as the latest techniques and solutions for effectively overcoming current obstacles. Register now.
|
|
By Kevin Dunleavy Early this month at an investor event, Bayer CEO Bill Anderson declared that employees “are ready for change." On Wednesday, Anderson answered the call with changes to the company’s leadership. In the pharma sector, Bayer revealed a new Global Commercialization unit, which will be led by Christine Roth. The company also tabbed Sebastian Guth as its chief operating officer. |
By Gabrielle Masson A new immuno-oncology biotech has emerged, clasping $150 million that will go toward developing next-gen T cell engagers (TCEs) targeting a range of hard-to-treat tumors. |
By Zoey Becker Idorsia's Tryvio is the first oral anti-hypertensive therapy that uses a new therapeutic mechanism in nearly 40 years, suggesting the dawn of "a new era of endothelin research," the company said. |
By Andrea Park As its high-dose Eylea continues to duke it out with Roche’s Vabysmo to be the go-to treatment for age-related macular degeneration and diabetic macular edema, Regeneron is hitching its wagon to several constellations’ worth of stars. |
By Max Bayer Acelyrin's subcutaneous thyroid eye disease treatment posted proof-of-concept data that were similar to Amgen's Tepezza. The readout is the latest in a wave of data that's fortified the biotech's 2024 comeback effort. |
By Angus Liu Bristol Myers Squibb is gunning for newly diagnosed unresectable liver cancer—again—after its Opdivo monotherapy setback five years ago and a subsequent market withdrawal. |
By Nick Paul Taylor Ted Danson has teamed up with Bristol Myers Squibb to show how plaque psoriasis patients can get to a good place. The actor, who developed psoriasis aged 25, is fronting a new campaign to show how BMS’ Sotyktu can help alleviate physical, mental and social burdens linked to the skin condition. |
By Fraiser Kansteiner,Angus Liu In a bid to corner contracts on next-generation medicines, production juggernaut Lonza is picking up one of the world’s biggest biologics manufacturing facilities from its Swiss compatriot Roche. |
By Conor Hale After the deal for MDC closes, it is set to operate as a standalone company led by its current management, according to Montagu. |
By Ben Adams Medical testing company Qiagen is joining forces with the International Panel Physicians Association (IPPA) to boost awareness around tuberculosis testing. |
Fierce podcastsDon’t miss an episode |
| | In this episode of 'The Top Line,' Fierce Biotech Senior Editor Annalee Armstrong interviews Karen Correa, Ph.D., from Takeda, discussing the crucial need for pharmaceutical companies to prioritize diversity in clinical trials. |
|
|---|
|
|
|
Monday, April 22, 2024 | 10am ET / 7am PTExplore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now!
|
|
| WhitepaperExplore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
| Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
